Previous Article | Next Article 
Journal of Virology, April 1999, p. 2790-2797, Vol. 73, No. 4
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Effect of the Attenuating Deletion and of Sequence
Alterations Evolving In Vivo on Simian Immunodeficiency Virus
C8-Nef Function
Silke
Carl,1
A.
John
Iafrate,2
Jacek
Skowronski,2
Christiane
Stahl-Hennig,3 and
Frank
Kirchhoff1,*
Institute for Clinical and Molecular
Virology, University of Erlangen-Nuernberg, 91054 Erlangen,1 and German Primate
Center, 37077 Göttingen,3 Germany, and
Cold Spring Laboratory, Cold Spring Harbor, New York
117242
Received 13 October 1998/Accepted 3 January 1999
 |
ABSTRACT |
The simian immunodeficiency virus macC8 (SIVmacC8) variant has been
used in a European Community Concerted Action project to study the
efficacy and safety of live attenuated SIV vaccines in a large number
of macaques. The attenuating deletion in the SIVmacC8
nef-long terminal repeat region encompasses only 12 bp and
is "repaired" in a subset of infected animals. It is unknown whether C8-Nef retains some activity. Since it seems important to use
only well-characterized deletion mutants in live attenuated vaccine
studies, we analyzed the relevance of the deletion, and the
duplications and point mutations selected in infected macaques for Nef
function in vitro. The deletion, affecting amino acids 143 to 146 (DMYL), resulted in a dramatic decrease in Nef stability and function.
The initial 12-bp duplication resulted in efficient Nef expression and
an intermediate phenotype in infectivity assays, but it did not
significantly restore the ability of Nef to stimulate viral replication
and to downmodulate CD4 and class I major histocompatibility complex
cell surface expression. The additional substitutions however, which
subsequently evolved in vivo, gradually restored these Nef functions.
It was noteworthy that coinfection experiments in the T-lymphoid 221 cell line revealed that even SIVmac nef variants carrying
the original 12-bp deletion readily outgrew an otherwise isogenic virus
containing a 182-bp deletion in the nef gene. Thus,
although C8-Nef is unstable and severely impaired in in vitro assays,
it maintains some residual activity to stimulate viral replication.
 |
INTRODUCTION |
Studies with the simian
immunodeficiency virus (SIV) macaque model have shown that an intact
nef gene is critical for efficient replication and the
development of AIDS (23). Premature stop codons in the
nef open reading frame (ORF) reverted to open forms within
the first 2 weeks after infection, resulting in subsequent disease
progression. In contrast, nef-deleted forms did not induce disease, showed very low levels of p27 plasma viremia during the acute
phase of infection, and an approximately 100- to 1,000-fold reduced
cell-associated viral load in the postacute phase (23). Under certain experimental conditions, however, when neonatal monkeys
born to unvaccinated mothers are infected with extremely high doses of
virus soon after delivery, even nef-defective SIV variants
are pathogenic (6, 46). Several studies have demonstrated that some long-term nonprogressors of human immunodeficiency virus type
1 (HIV-1) infection harbor nef-defective forms of HIV-1, suggesting that an intact nef gene is of similar importance
for human AIDS pathogenesis (13, 25, 36).
Although an intact nef gene has a drastic effect on viral
replication in vivo, it is dispensable for efficient replication in
most in vitro cell culture systems. It is largely unclear how Nef
enhances viral replication in vivo. However, several in vitro activities of Nef that may potentially play a role in the pathogenesis of AIDS have been established. Nef increases the infectivity of viral
particles (8, 27, 28, 42). This effect may involve a
modification of the virions that results in more-efficient reverse transcription (2, 8, 31, 37). Furthermore, Nef stimulates viral replication in primary lymphocytes and in the T-lymphoid 221 cell
line (3, 27, 42). The enhancement of viral particle infectivity or the activation of the large pool of quiescent T lymphocytes in vivo could directly enhance viral spread in vivo. Nef
downregulates the cell surface expression of CD4 (1, 15, 17)
and of class I major histocompatibility complex (MHC) molecules (9, 38). Downregulation of CD4 may prevent superinfection, promote viral particle release, and impair T-helper-cell functions, and
downmodulation of MHC class I molecules may allow evasion of
cytotoxic-T-lymphocyte (CTL) lysis by HIV-1-infected cells.
The important role of nef in pathogenesis has made it an
important target for the development of live attenuated AIDS vaccines. Rhesus macaques that were infected with nef-deleted forms of
SIVmac239 were fully protected against subsequent challenge with high
doses of heterologous pathogenic SIV (11). The efficacy of
live attenuated SIV vaccines has been confirmed in a number of
independent studies (4, 40, 46). An SIVmac variant
containing a large deletion of 182 bp in the nef-unique
region was used in the initial study to minimize the risk of reversion
and to ensure that nef function is completely disrupted
(23). Subsequent studies showed that more than 300 bp of
upstream regulatory U3 sequences of the long terminal repeat (LTR)
serve mainly as a Nef coding region (21, 24). The multiple
deleted SIV mutants currently used for the development of a life
attenuated AIDS vaccine in the United States contain deletions of 182 bp in the nef-unique region and of approximately 300 bp in
the U3 region (46), thus removing about 66% of the entire
nef gene.
In studies of the European Community Concerted Action project designed
to examine the mechanism of immune protection and the safety of live
attenuated vaccines, a naturally occurring SIVmac variant (C8) has been
commonly used (5, 10, 14, 30, 39, 43, 44). The SIVmacC8
clone was derived from the pathogenic SIVmac32H isolate
(34). The major difference of the attenuated C8 variant from
the pathogenic J5 clone, which was obtained from the same animal
infected with the 32H isolate, is an in-frame deletion of just 12 bp in
the nef gene (35). In the deduced C8-Nef sequence
amino acids (aa) 143 to 146 (DMYL) are missing. It has been shown, that
this deletion can be repaired in vivo by a sequence duplication of 12 bp (14, 43, 45). Subsequently, the duplicated region
continues to evolve until it is virtually indistinguishable from the
functional wild-type sequence (4-aa deletion
EKIL
EIYL
DIYL; wild type, DMYL) (45). The reversions in
nef are associated with increased virulence and with the
development of immunodeficiency, indicating that this region in
nef is important for the full replicative potential in vivo
(14, 43, 45).
Studies in a great number of rhesus macaques have established that the
SIVmacC8 Nef variant has an attenuated phenotype in vivo (5, 10,
14, 30, 39, 43-45). However, 98.5% of the nef ORF is
still intact, and an almost full-length Nef protein could be expressed.
It is unknown whether the SIVmacC8 variant is fully attenuated, or
whether it expresses a Nef protein that is partly active. Therefore, we
have investigated C8-Nef variants containing the original deletion of
aa 143 to 146, as well as forms with the predicted repaired sequences
EKIL, EKFL, EIYL, DIYL, and DMYL, in well-established in vitro assay
systems for Nef function. Protein stability and the ability of Nef to
downregulate CD4 and MHC class I surface expression and to enhance
virion infectivity and viral replication were impaired by the 4-aa
deletion, and functional activity was gradually restored by the
duplication and point mutations evolving in infected macaques. However,
our results also demonstrate that the C8-nef allele still
provides a replicative advantage in a T-lymphoid cell line, suggesting that it maintains some activity in promoting viral replication in vivo.
 |
MATERIALS AND METHODS |
DNA analysis.
SIV nef genes were amplified by
nested PCR (24) directly from peripheral blood mononuclear
cell (PBMC) DNA derived from two macaques infected with the SIVmacC8
clone, Mm1820 (at 15 and 42 weeks postinfection) and Mm1823 (at 15, 20, and 42 weeks postinfection), which had developed signs of
immunodeficiency (14, 43). For the first round of PCR
amplification, primers p90 (5'-CTATCGAGAGTATACCAGATCC-3' positions 9230 to 9251) and p41
(5'-TCTGCCAGCCTCTCCGCAGAGCG-3', positions 10239 to 10261)
were used. For the second round of amplification, 5 µl of the
100-µl reaction mixture was used with primers p91 (5'-ATACTCCAGAGGCTCTCTGC-3', positions 9260 to 9279) and p42
(5'-CGACTGAATACAGAGCGAAATGC-3', positions 10218 to 10240).
The numbering corresponds to the SIVmac239 sequence (33).
PCR fragments were gel purified with the Quiaquick gel extraction kit
(Diagen, Basel, Switzerland) and sequenced directly or after cloning
into an expression vector. Sequencing was performed with the Prism
sequencing kit (Perkin-Elmer, Foster City, Calif.) and with an Applied
Biosystems 373 DNA sequencer according to the protocols of the
manufacturers. Sequences were analyzed by using the GCG sequence
analysis software-package (Genetics Computer Corp.).
Construction of SIVmac239
C8 and SIVmacC8 Nef variants.
Site-directed mutagenesis to generate the C8 variants EKIL, EIYL, and
DMYL and the deletion mutant 239
C8 was performed by spliced overlap
extension PCR with mutagenic internal primers (19). Briefly,
the env-nef region was amplified with primers P1
(5'-ACCTATCTAGAATATGGGTGGAGC-3', positions 9333 to 9343; boldface letters indicate an XbaI restriction site)
and P3 (5'-TAAGATTCTATGTCTTCTTGC-3', positions 9737 to
9758). The nef-LTR region was amplified with primers P2
(5'-GTCCCTACGCGTCAGCGAGTTTCCTTCTTG-3'), which binds to bases 10106 to 10124 of the SIVmac239 sequence and contains an
MluI restriction site (indicated in boldface), and P4 EKIL (5'-GACATAGAATCTTAGAGAAGATCTTAGAAAAGGAGG-3',
positions 9745 to 9780), P4 EIYL
(5'-GACATAGAATCTTAGAGATTTACTTAGAAAAGGAGG-3',
positions 9745 to 9780), P4 DMYL
(5'-GACATAGAATCTTAGACATGTACTTAGAAAAGGAGG-3'; positions 9745 to 9780), or P4
C8
(5'-GAAGACATAGAATCTTAGAAAAGGAAGAAGGCATC-3'), which bind to
nucleotides 9741 to 9758 and nucleotides 9771 to 9788. Mm1823 K1
recovered at 20 weeks postinfection was used as template to generate
the EKIL, EIYL, and DMYL variants. Numbers refer to the published
SIVmac239 sequence (33), and mutated positions are
underlined. The left- and right-half PCR products were gel purified,
mixed at equimolar amounts, subjected to a second PCR with primers P1
SIV XbaI and P2 SIV MluI, and then gel purified.
For Nef expression in Jurkat T cells, the nef variants were
inserted into a T-cell-specific pCD3-
expression vector by using the
unique XbaI and MluI sites. Sequence analysis of the PCR-derived inserts confirmed that only the intended changes were
present. To construct the proviral clones, the PCR products were
inserted into a modified pBR322 vector containing the full-length SIVmac239 proviral DNA by using the unique NheI and
EcoRI sites in the SIV envelope and the vector sequences
flanking the 3' end of the provirus as described elsewhere
(26). Two nef-defective controls were used,
SIVmac239 nef* contains a premature in-frame TAA stop signal
at the 93rd codon of nef and SIVmac239
Nef contains a
182-bp deletion in nef (23).
Production of virus stocks.
Generation of virus stocks was
performed by the calcium phosphate method essentially as described
earlier (12). Briefly, 293T cells were transfected with 5 µg of the full-length proviral SIVmac239 constructs differing only in
the nef gene. After overnight incubation, the medium was
changed and virus was harvested 24 h later. Viral stocks were
aliquoted and frozen at
80°C; p27 antigen concentrations of viral
stocks were then quantitated by using a commercial HIV-1-HIV-2
enzyme-linked immunosorbent assay (Immunogenetics, Zwijndrecht, Belgium).
Cell culture, infectivity, and viral replication.
293T and
sMAGI cells were grown in Dulbecco modified Eagle medium supplemented
with 10% fetal calf serum (FCS). Infection of sMAGI cells was
performed as described previously (7), except that no
DEAE-dextran was added. Viral infectivity was quantitated with the
Galacto-Light Plus Chemoluminescence Reporter Assay Kit (Tropix,
Bedford, Mass.) as recommended by the manufacturer. The Herpesvirus saimiri-transformed T-cell line 221 (3) was maintained in the presence of 100 U of interleukin-2
(IL-2) per ml (Boehringer, Heidelberg, Germany) and 20% FCS, and
infections were performed in the presence of 50 U of IL-2 per ml and
with 5% FCS as described previously. Supernatants were collected at 3- or 4-day intervals, and virus production was measured by reverse
transcriptase assay as described previously (32).
Nef expression in infected CEMx174 cells.
CEMx174 cells were
infected with virus containing 10 ng of p27 core antigen derived from
transfected 293T cells. When cytopathic effects were observed, cells
were pelleted and lysates were generated as described previously
(29) and then separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis in 12% polyacrylamide. Nef
proteins were detected by Western blot analysis with rabbit anti-Nef-serum. For detection of p27 core protein an anti-gag serum
derived from SIVmac p27 hybridoma cells (55-2F12) was used (18). For enhanced chemiluminescence (ECL) detection,
horseradish peroxidase-conjugated secondary antibodies were used.
Nef expression in transfected 293T cells.
293T cells were
cotransfected with 20 µg of expression plasmid encoding for the
different Nef variants and 5 µg of
-galactosidase reporter
plasmid. Nef expression was detected by ECL immunoblotting with rabbit
anti-Nef serum.
-Galactosidase activity in the lysed cellular
extracts was quantitated with the Galacto-Light Plus Chemoluminescence
Reporter Assay Kit as recommended by the manufacturer.
Functional analysis.
Dose-response analysis of the effect of
Nef on CD4 and MHC class I cell surface expression were assayed as
described previously (16, 20, 41). Briefly, the JJK subline
of Jurkat T cells was cotransfected by electroporation with a CD20
expression plasmid and various amounts of Nef expression plasmid and
carrier DNA. The cell surface expression of CD4, CD20, and MHC class I
was analyzed 30 to 36 h after transfection by using an Epics-Elite flow cytometer.
Coinfection of 221 cells.
To detect even modest differences
in the replication of SIVmac Nef variants, 2.5 million 221 cells were
seeded into 24-well plates, coinfected with two virus stocks (each
containing 10 ng of p27 antigen), and cultured in the presence of 50 U
of IL-2 per ml. In weekly intervals, 50 µl of cell-free supernatant
was used to infect a fresh 221 cell culture, and the infected cells were pelleted to extract genomic DNA. Subsequently, the
nef-LTR region was amplified, and the PCR products were
analyzed by electrophoresis through 1.5% agarose gels and then
sequenced as described previously (26).
 |
RESULTS |
Repair of the 12-bp deletion in vivo.
Two of eight rhesus
macaques inoculated with the SIVmacC8 variant at the German Primate
Center developed signs of immunodeficiency at weeks 38 (Mm1820) and 28 (Mm1823) after infection (14, 43). The other six monkeys,
two preinfected for 42 weeks and four preinfected for 22 weeks,
resisted challenge with pathogenic SIV and remained asymptomic, with
low viral loads, throughout the 2-year observation period (14,
43). We amplified the entire nef genes from sequential PBMC samples drawn from the progressing macaques in order to obtain nef alleles similar to that of the input C8 provirus and
repaired forms selected in vivo for functional analysis. No changes in the deleted region were detected in proviral nef sequences
recovered from Mm1820 at 15 weeks postinfection. However, four of five
nef sequences derived from Mm1820 at 42 weeks postinfection
contained an almost perfect 12-bp repeat, substituting the 4-aa
deletion with the predicted sequence EKFL (Fig.
1). Three of these four sequences also
contained a downstream deletion of 30 bp, predicting deletion of aa 189 to 198. From the second animal, Mm1823, three sequential PBMC samples
obtained at 15, 20, and 42 weeks postinfection were analyzed. Three of
four nef sequences obtained from the earliest time point
still contained the deletion, and one contained an almost perfect 12-bp
duplication, with the predicted amino acid sequence EKVL. In contrast,
all nef sequences derived from the 20- and
42-weeks-postinfection time points contained an amino acid sequence
(DIYL) identical to the SIVmac239 Nef (Fig. 1).

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 1.
Alignment of the predicted Nef amino acid sequences
analyzed. In the upper part of the figure Nef sequences detected in
Mm1820 and Mm1823 are shown. The animal number is indicated in the left
column. The two-digit numbers in the right column give the number of
weeks postinfection, and the number after the dash specifies the
individual clone. The predicted amino acid sequences of the J5- and
C8-Nef variants; the constructed EKIL-, EIYL-, and DMYL-Nef mutants;
and the 239wt, 239 C8, and nef* variants are shown
underneath. The consensus sequence is given on the bottom line.
Symbols: , identity with the consensus Nef sequence; · , gaps
introduced to optimize the alignment; *, a stop signal; and X,
nef alleles selected for functional analysis. The deleted
region of aa 143 to 146, which is repaired in vivo, is shaded.
|
|
Selection of nef alleles for functional analysis.
Two sets of nef alleles were selected to assess the
functional relevance of the 4-aa deletion and the duplications and
point mutations that evolved in vivo. The first set consisted of
representative nef alleles obtained for each time point of
sampling from Mm1820 and Mm1823 (Fig. 1). This set included the Mm1820
15-1 Nef, which contains the original 4-aa deletion (1820
C8); the
Mm1820 42-1Nef, which contains the sequence EKFL in conjunction with a
deletion of aa 189 to 198 (1820EKFL
10); the Mm1823 15-2Nef, which
also contained the 4-aa deletion (1823
C8); and the Mm1823 20-3Nef (1823DIYL20) and the 42-2 Nef (1823DIYL42), which contain the same
amino acid sequence (DIYL) as the wild-type Nef. The second set
included three C8-Nef variants with the predicted repaired sequences
EKIL, EIYL, and DMYL that have been observed in a previous study
(45). These three variants were constructed by mutagenesis. As an additional control, the region corresponding to the 12-bp deletion in the C8 nef was removed from the nef
gene of the pathogenic SIVmac239 clone (239
C8) (Fig. 1).
Deletion of aa 143 to 146 reduces Nef steady-state expression
levels.
The deletion in the C8-Nef is located in the highly
conserved core of the Nef protein and may affect stability. To
investigate whether the mutated Nef proteins are expressed in infected
cells, the virus stocks generated by transient transfection of 293T
cells were used to infect the T/B hybrid CEMx174 cell line. The
wild-type (239wt) Nef protein was efficiently synthesized in the
infected cells, whereas no Nef-specific signal could be detected in
cells infected with the nef* control virus (Fig.
2A). Only low amounts of Nef could be
detected in cells infected with the SIVmac239
C8 and 1823
C8
nef variants carrying the 12-bp deletion. In contrast, comparable amounts of p27 capsid antigen were detected, indicating that
all cell cultures were efficiently infected. All six nef alleles containing duplications (EKIL, EIYL, DMYL, 1820EKFL
10, 1823DIYL20, and 1823DIYL42) were efficiently expressed
(Fig. 2A). To confirm these results in an independent assay, 293T cells
were transiently cotransfected with plasmids expressing Nef and
-galactosidase. Western blot analysis revealed efficient expression
of the 239Nef and the EKIL- and DMYL-Nef proteins (Fig. 2B). In
contrast, only very low amounts of the 1823
C8 and 239
C8 Nef
proteins could be detected. The low levels of the 1823
C8 and
239
C8 Nef proteins in the 293T cells did not result from low
transfection efficiencies, since the quantities of
-galactosidase
activity in the cellular extracts were comparable to those observed in
the cells transfected with the 239Nef expression vector (Fig. 2B).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 2.
Deletion of aa 143 to 146 reduces Nef steady-state
expression levels. (A) Detection of viral proteins in CEMx174 cells
infected with SIVmac239 containing wild-type or mutant nef
genes. CEMx174 cells were infected with viral stocks containing 10 ng
of p27 core antigen (derived from 293T cells transiently transfected
with the proviral Nef mutant constructs indicated) and cultured until
cytopathic effects were observed. Uninfected CEMx174 cells were used as
negative control. (B) 293T cells were cotransfected with 20 µg of
expression plasmid encoding the indicated Nef proteins and 5 µg of
-galactosidase reporter plasmid. As a negative control, empty pFJ-EA
vector was used. ECL immunoblot and quantitation of -galactosidase
activity were performed as described in the Materials and Methods.
|
|
Repair of the 12-bp deletion gradually restores the ability of Nef
to stimulate viral replication and to enhance virion infectivity.
Replication of SIVmac in the Herpesvirus saimiri-transformed
T-lymphoid rhesus cell line 221 in the absence of IL-2 depends on the
presence of an intact nef gene, and this cell culture system may represent a model for evaluating the ability of Nef to cause lymphoid-cell activation (3). At low levels of IL-2 in the culture medium, Nef variants containing a premature stop codon (239nef*), the 12-bp deletion (Mm1823
C8), or the initial
duplication (EKIL) replicated very inefficiently (Fig.
3). Variants carrying the 1823DIYL20 and
EIYL nef alleles showed marginally increased replication. In
contrast, the DMYL-Nef showed an intermediate phenotype, and the form
selected late in infection of Mm1823 (1823DIYL42) was fully active
(Fig. 3). Results obtained with different preparations of rhesus PBMC,
which were infected at a low multiplicity of infection and stimulated 3 or 6 days later, were similar to those obtained with 221 cells but were
more variable (data not shown). In contrast, all Nef variants
replicated with comparable efficiency in CEMx174 cells (Table
1).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 3.
Growth of SIVmac239 and SIVmacC8 Nef variants in the
Herpesvirus saimiri-transformed rhesus monkey T-cell line
221. Cells were propagated in the presence of a low amount of IL-2 (50 U/ml). Virus stocks containing 10 ng of p27 antigen were used for
infection, and production was monitored by reverse transcriptase assay
at the indicated days postinfection. Similar results were obtained in
three independent experiments. P.S.L. = photo-stimulated light
emission.
|
|
The same virus stocks were used to assess the influence of the 4-aa
deletion and the reversions on virion infectivity in sMAGI
cells. This
cell line is a derivative of a rhesus macaque mammary
tumor cell line
engineered to express human CD4 and containing
an integrated copy of a
truncated HIV-1 LTR fused to the

-galactosidase
gene (
7).
As shown in Fig.
4, defects in the
nef gene decreased
viral infectivity for sMAGI cells by
approximately 8- to 10-fold
(239nef*, 11.6 ± 1.4%;

nef,
13.6 ± 2.3%). Nef alleles carrying
the 12-bp deletion (239

C8,
1820

C8, and 1823

C8) increased virion
infectivity only marginally
to 16 to 23% of the level of the SIVmac239wt
control (Fig.
4 and Table
1). The initial duplications resulted
in an intermediate phenotype, and
the additional amino acid substitutions
selected in Mm1823 later in
infection fully restored the ability
of Nef to increase virion
infectivity (Fig.
4 and Table
1).

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 4.
Infectivity of SIVmac239 and SIVmacC8 Nef variants.
sMAGI cells were infected in triplicate with virus containing 100 ng of
p27 antigen derived from transient transfection of 293T cells.
-Galactosidase activities were assayed at 3 days postinfection. The
average values relative to wild type obtained from five experiments
performed with different virus stocks are shown.
|
|
Restoration of CD4 and MHC-I downmodulation.
The
nef alleles were cloned into a T-cell-specific expression
vector. Transient transfection of the 293Nef expression plasmid into
Jurkat T cells resulted in a dose-dependent downregulation of CD4 cell
surface expression (Fig. 5A). At the
highest amount (20 µg) of expression plasmid, an approximately
20-fold effect was observed. In contrast, nef alleles
carrying the 12-bp deletion or an early duplication (EKIL) showed only
marginal activity even at the highest concentrations (Fig. 5A). It
remains to be elucidated whether the EKIL-Nef is impaired in CD4
internalization or in subsequent sorting to the lysosome. However,
nef alleles that evolved later in infection (EIYL, DMYL, and
1823DIYL42) were able to downregulate CD4 surface expression, albeit
with reduced efficiency compared to the 239wt Nef. The 1820EKFL
10
nef, carrying a downstream deletion of 30 bp in addition to
the 12-bp duplication, was inactive in CD4 downregulation.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 5.
Downmodulation of CD4 (A) and MHC class I (B) surface
expression by SIVmacC8 variants. Jurkat T cells were transfected with
the indicated amounts of vectors expressing the SIVmac239 and C8
nef genes. CD4 and MHC class I expression on the cell
surface was determined by flow-cytometric analysis.
|
|
Similar to the results obtained upon CD4 downmodulation, the 1823

C8
and 1820EKFL

10 Nef proteins were unable to downregulate
MHC-I
surface expression (Fig.
5B). In contrast, EIYL, DMYL, and
1823DIYL42
showed an activity comparable to 239wt Nef and resulted
in a reduction
of MHC-I surface expression of up to 10-fold. The
EKIL and 1823DIYL20
nef alleles showed an intermediate activity
(Fig.
5B).
The 12-bp deletion does not completely disrupt the ability of Nef
to increase viral replication in 221 cells.
Our results showed
that deletion of aa 143 to 146 impairs Nef expression and has
pleiotropic effects on in vitro activities (summarized in Table 1).
However, it seemed that even the nef alleles containing the
12-bp deletion still maintained some marginal activity in infectivity
enhancement as well as in CD4 and MHC-I downmodulation. In particular,
viral replication and infectivity assays are somewhat variable and
modest differences are difficult to demonstrate. To detect subtle
differences in replicative capacity in vitro, 221 cells were coinfected
with SIVmacC8-Nef variants and viruses carrying a deleted or a
full-length nef. As shown in Fig.
6, the SIVmac239wt variant rapidly
outgrew the isogenic nef-deleted forms. After coinfection of
221 cells with SIVmac239
Nef and the 239
C8 or 1823
C8 Nef
variants, both the forms carrying the 12-bp deletion and the 182-bp
deletion in nef were detected after the first passage (Fig.
6, upper panel). After the second passage, however, the 12-bp deletion
mutants became predominant, and for the last two passages the
nef allele with the 182-bp deletion was not detected (Fig.
6). In contrast, when 221 cells were coinfected with SIVmac239wt and
the forms with the 12-bp deletions, only the wild-type 239nef could be
detected by direct sequence analysis of PCR fragments (Fig. 6, lower
panel). Similarly Nef variants containing duplications (EKIL and DMYL)
outgrew the virus containing the nef gene with the original
12-bp deletion. These results show that the variants containing the
duplications selected for in vivo have a higher replicative potential
than the C8-Nef variant. However, even the nef alleles
carrying the original 12-bp deletion maintained some residual activity
to stimulate SIV replication in this T-lymphoid cell line.

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 6.
Coinfection of 221 cells with SIVmac239 and SIVmacC8 Nef
variants. 221 cells were infected with equal amounts of p27 antigen (10 ng) of the mutants indicated. At weekly intervals the supernatant was
used to infect a new culture (passages 1 to 4), and the cells were used
for extraction of genomic DNA. The nef gene was amplified
from 221 cells coinfected with the Nef variant and the other
variants indicated, and the PCR products were separated on a 1.5%
agarose gel (upper panel). In the lower panel, the results of direct
sequence analysis of DNA fragments spanning nef are shown.
Sequence analysis was performed as described previously
(26). Levels of nef alleles carrying the C8
deletion were always below 10%. The results are shown for 221 cells
that were grown in the presence of 50 U of IL-2 per ml. Abbreviations:
K, uninfected CEMx174 cells; Nef, SIVmac239 Nef.
|
|
 |
DISCUSSION |
We have found that the deletion of aa 143 to 146 in
SIVmacC8-Nef, which clearly attenuates SIV replication in vivo
(4, 5, 10, 14, 30, 34, 39, 43-45), disrupts Nef function in
vitro. The deletion also impaired Nef expression, thus explaining the
pleiotropic effects on functional activity. The early 12-bp duplications (EKFL and EKIL) selected in vivo resulted in stable Nef
protein expression but had only marginally restorative effects on the
ability of Nef to stimulate viral infectivity and replication and to
downmodulate CD4 and MHC-I. This indicates that the deleted region in
Nef is important for proper folding of the Nef molecule. In vivo,
additional amino acid substitutions were selected and the evolution of
the 4-aa region to sequences similar or identical to that present in
the Nef proteins of the pathogenic SIVmac239 and SIVmacJ5 variants was
associated with increasing viral loads and disease progression
(14, 43, 45). In agreement with the selective pressure
observed in vivo, functional analysis revealed that these amino acid
substitutions gradually almost fully restored all of the in vitro Nef
activities investigated. The restorative effects of the various
duplications varied slightly between the different in vitro assay
systems. This can best be compared for the constructed EKIL-, EIYL-,
and DMYL-Nef variants that are otherwise isogenic to each other and to
the C8-Nef. The initial duplication (EKIL) had a moderate restorative
effect on infectivity and on MHC-I downregulation but not on the
downmodulation of CD4. A replicative advantage of the EKIL-Nef variant,
compared to the C8-Nef variant, in 221 cells could only be demonstrated
by coinfection experiments. With the exception of two amino acid
substitutions, K181R and A249T, the constructed DMYL-Nef is identical
to that of the J5 clone but differs at 15 aa positions from the 239Nef
(Fig. 1). The DMYL-Nef showed an activity comparable to the 239Nef in
the enhancement of infectivity and in MHC-I downregulation but was less
active in CD4 downmodulation and in its ability to stimulate viral
replication. In contrast to the highly pathogenic SIVmac239 clone
(22), the J5 virus has been reported to be only moderately pathogenic (35). It seems possible that the higher
pathogenicity of SIVmac239 is due to a more active nef allele.
Our results show that even the 12-bp deletion nef variants
have some residual activity to stimulate viral replication, although only very low amounts of the deleted Nef protein could be detected in
infected cells. Similarly, these variants seemed to retain some
marginal activity in other in vitro assay systems for Nef function.
These findings may explain why, in contrast to macaques infected with
SIV nef variants containing a 182-bp deletion in nef (24), no additional large deletions in the U3
region have been found in macaques infected with the C8 variant. The
residual activity may provide a selective advantage over forms in which the nef gene is completely disrupted. It has been described
that the C8-Nef can be detected in infected cells (45) and
that it can induce CTL responses (14). Macaques infected
with the C8 variant seem to be more rapidly protected against challenge
with pathogenic SIV than are animals vaccinated with the SIVmac239 variant containing the 182-bp deletion in nef (30,
43). Since protection is linked to the replicative capacity of
the vaccine virus (46), these previous results also
suggested that the C8-Nef may not be entirely inactive.
In one of the animals infected with the C8-Nef variant (Mm1823) our
findings were similar to those of Whatmore et al. (45). They
noted an almost perfect 12-bp duplication event and a subsequent evolution to forms that are indistinguishable from the wild-type Nef.
In this animal functional Nef activity was also fully restored, and
most nef genes detected at later time points were intact. Mm1823 showed declining CD4/CD8 ratios by between 20 and 32 weeks postinfection and progressing peripheral lymphadenopathy beginning at
week 42 (14, 43). The 1823DIYL20 Nef, which was obtained when the animal started to develop signs of immunodeficiency (14, 43), showed an intermediate phenotype in in vitro assays for Nef
function (summarized in Table 1). The 1823DIYL42 nef allele, obtained when more severe clinical alterations were observed, was
almost fully active. This form contains the same 4-aa repair as the
1823DIYL20 Nef, but it differs at 8 other amino acid positions (Fig.
1). Thus, the higher functional activity of the 1823DIYL42 Nef may be
due to the presence of these additional amino acid substitutions. In
particular, the Q196H change may be relevant for Nef function and
increased viral pathogenicity, since this change is also present in the
Nef protein of the highly pathogenic SIVmac239 Nef and has been
observed in other C8-infected macaques (45). Surprisingly,
three of four "repaired" nef alleles derived from the
second animal, Mm1820, at 42 weeks postinfection contained a downstream
deletion of 30 bp, predicting deletion of Nef aa 189 to 198. We have
not observed similar in-frame deletions in the nef gene of
14 SIVmac239wt-infected animals (25a). However, Sharpe et
al. (39) have observed a similar deletion of 33 bp (removing
aa 193 to 203), which evolved after the 12-bp duplication. The
nef allele carrying the 30-bp deletion together with a 12-bp duplication (1820EKFL
10) was largely inactive in functional assays, and it remains to be elucidated why short in-frame deletions close to
the 3' end of the nef gene are selected in some animals
infected with the C8 variant. Mm1823 developed more-severe alterations than did Mm1820 that were indicative of an immunodeficiency (14, 43). Our observation that Nef function was fully restored in Mm1823, but not in Mm1820, is in agreement with these previous findings.
In summary, we have shown than an attenuated SIVmac variant that has
been broadly used for studies on live attenuated SIV vaccines
throughout Europe contains a nef gene that is largely defective in in vitro assay systems. In addition to the previous observation that the 12-bp deletion can be repaired to forms that are
indistinguishable from wild-type nef alleles (and thus also from the challenge virus), our finding that the C8-Nef still has some
residual activity, at least in the stimulation of viral replication, raises even more questions concerning the use of this variant for
studies of live attenuated AIDS vaccines.
 |
ACKNOWLEDGMENTS |
We thank Mandy Krumbiegel for technical assistance, Bernhard
Fleckenstein for support and encouragement, and Klaus Überla for
critical reading of the manuscript. We also thank Martin P. Cranage and
E. W. Rud for providing the C8 virus, Julie Overbaugh and Bryce
Chackerian for sMAGI cells, and Lou Alexander and Ronald C. Desrosiers
for the 221 cells. The SIVmac p27 hybridoma cells (55-2F12) were kindly
provided by Niels Petersen through the NIH AIDS Reagent Program.
This work was supported by the Public Health service grant TA-42561 to
J.S., the Deutsche Forschungsgemeinschaft, the Wilhelm-Sander Stiftung,
and the Bundesministerium für Forschung und Technologie.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institute for
Clinical and Molecular Virology, University of Erlangen-Nuernberg,
Schlossgarten 4, 91054 Erlangen, Germany. Phone: 49-9131-852-6483. Fax:
49-9131-852-2101. E-mail:
fkkirchh{at}viro.med.uni-erlangen.de.
 |
REFERENCES |
| 1.
|
Aiken, C.,
J. Konner,
N. R. Landau,
M. E. Lenburg, and D. Trono.
1994.
Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain.
Cell
76:853-864[Medline].
|
| 2.
|
Aiken, C., and D. Trono.
1995.
Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis.
J. Virol.
69:5048-5056[Abstract].
|
| 3.
|
Alexander, L.,
Z. Du,
M. Rosenzweig,
J. J. Jung, and R. C. Desrosiers.
1997.
A role for natural SIV and HIV-1 nef alleles in lymphocyte activation.
J. Virol.
71:6094-6099[Abstract].
|
| 4.
|
Almond, N.,
K. Kent,
M. Cranage,
E. Rud,
B. Clarke, and E. J. Stott.
1995.
Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells.
Lancet
345:1342-1344[Medline].
|
| 5.
|
Almond, N.,
J. Rose,
R. Sangster,
P. Silvera,
R. Stebbings,
B. Walker, and E. J. Stott.
1997.
Mechanisms of protection induced by attenuated simian immunodeficiency virus. Protection cannot be transferred with immune serum.
J. Gen. Virol.
78:1919-1922[Abstract].
|
| 6.
|
Baba, T. W.,
Y. S. Jeong,
D. Pennick,
R. Bronson,
M. F. Greene, and R. M. Ruprecht.
1995.
Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques.
Science
267:1820-1825[Abstract/Free Full Text].
|
| 7.
|
Chackerian, B.,
N. L. Haigwood, and J. Overbaugh.
1995.
Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates.
Virology
213:386-394[Medline].
|
| 8.
|
Chowers, M. Y.,
C. A. Spina,
T. J. Kwoh,
N. J. Fitch,
D. D. Richman, and J. C. Guatelli.
1994.
Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene.
J. Virol.
68:2906-2914[Abstract/Free Full Text].
|
| 9.
|
Collins, K. L.,
B. K. Chen,
S. A. Kalams,
B. D. Walker, and D. Baltimore.
1998.
HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.
Nature
391:397-401[Medline].
|
| 10.
|
Cranage, M. P.,
A. M. Whatmore,
S. A. Sharpe,
N. Cook,
N. Polyanskaya,
S. Leech,
J. D. Smith,
E. W. Rud,
M. J. Dennis, and G. A. Hall.
1997.
Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa.
Virology
229:143-154[Medline].
|
| 11.
|
Daniel, M. D.,
F. Kirchhoff,
S. C. Czajak,
P. K. Sehgal, and R. C. Desrosiers.
1992.
Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.
Science
258:1938-1941[Abstract/Free Full Text].
|
| 12.
|
Deng, H.,
R. Liu,
W. Ellmeier,
S. Choe,
D. Unutmaz,
M. Burkhart,
P. Di Marzio,
S. Marmon,
R. E. Sutton,
C. M. Hill,
C. B. Davis,
S. C. Peiper,
T. J. Schall,
D. R. Littman, and N. R. Landau.
1996.
Identification of a major co-receptor for primary isolates of HIV-1.
Nature
381:661-666[Medline].
|
| 13.
|
Deacon, N. J.,
A. Tsykin,
A. Solomon,
K. Smith,
M. Ludford-Menting,
D. J. Hooker,
D. A. McPhee,
A. L. Greenway,
A. Ellett, and C. Chatfield.
1995.
Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients.
Science
270:988-991[Abstract/Free Full Text].
|
| 14.
|
Dittmer, U.,
T. Nisslein,
W. Bodemer,
H. Petry,
U. Sauermann,
C. Stahl-Hennig, and G. Hunsmann.
1995.
Cellular immune response of rhesus monkeys infected with a partially attenuated nef deletion mutant of the simian immunodeficiency virus.
Virology
212:392-397[Medline].
|
| 15.
|
Garcia, J. V., and A. D. Miller.
1991.
Serine phosphorylation-independent downregulation of cell-surface CD4 by nef.
Nature
350:508-511[Medline].
|
| 16.
|
Greenberg, M. E.,
A. J. Iafrate, and J. Skowronski.
1998.
The SH3 domain-binding surface and an acidic motif in HIV-1 Nef regulate trafficking of class I MHC complexes.
EMBO J.
17:2777-2789[Medline].
|
| 17.
|
Guy, B.,
M. P. Kieny,
Y. Riviere,
C. Le Peuch,
K. Dott,
M. Girard,
L. Montagnier, and J. P. Lecocq.
1987.
HIV F/3' orf encodes a phosphorylated GTP-binding protein resembling an oncogene product.
Nature
330:266-269[Medline].
|
| 18.
|
Higgins, J. R.,
S. Sutjipto,
P. A. Marx, and N. C. Pedersen.
1992.
Shared antigenic epitopes of the major core proteins of human and simian immunodeficiency virus isolates.
J. Med. Primatol.
21:265-269[Medline].
|
| 19.
|
Horton, R. M.,
H. D. Hunt,
S. N. Ho,
J. K. Pullen, and L. R. Pease.
1989.
Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension.
Gene
77:61-68[Medline].
|
| 20.
|
Iafrate, A. J.,
S. Bronson, and J. Skowronski.
1997.
Separable functions of Nef disrupt two aspects of T cell receptor machinery: CD4 expression and CD3 signaling.
EMBO J.
16:673-684[Medline].
|
| 21.
|
Ilyinskii, P. O.,
M. D. Daniel,
M. A. Simon,
A. A. Lackner, and R. C. Desrosiers.
1994.
The role of upstream U3 sequences in the pathogenesis of simian immunodeficiency virus-induced AIDS in rhesus monkeys.
J. Virol.
68:5933-5944[Abstract/Free Full Text].
|
| 22.
|
Kestler, H. W.,
T. Kodama,
D. J. Ringler,
M. Marthas,
N. Pedersen,
A. Lackner,
D. Regier,
P. K. Sehgal,
M. D. Daniel, and R. C. Desrosiers.
1990.
Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus.
Science
248:1109-1112[Abstract/Free Full Text].
|
| 23.
|
Kestler, H. W.,
D. J. Ringler,
K. Mori,
D. L. Panicali,
P. K. Sehgal,
M. D. Daniel, and R. C. Desrosiers.
1991.
Importance of the nef gene for maintenance of high virus loads and for development of AIDS.
Cell
65:651-662[Medline].
|
| 24.
|
Kirchhoff, F.,
H. W. Kestler, and R. C. Desrosiers.
1994.
Upstream U3 sequences in SIV are selectively deleted in vivo in the absence of nef function.
J. Virol.
68:2031-2037[Abstract/Free Full Text].
|
| 25.
|
Kirchhoff, F.,
T. C. Greenough,
D. B. Brettler,
J. L. Sullivan, and R. C. Desrosiers.
1995.
Absence of intact nef sequences in a long-term, nonprogressing survivor of HIV-1 infection.
N. Engl. J. Med.
332:228-232[Free Full Text].
|
| 25a.
| Kirchhoff, F., and C. Stahl-Hennig. Unpublished
observations.
|
| 26.
|
Lang, S. M.,
A. J. Iafrate,
C. Stahl-Hennig,
E. M. Kuhn,
T. Nisslein,
M. Haupt,
G. Hunsmann,
J. Skowronski, and F. Kirchhoff.
1997.
Association of simian immunodeficiency virus Nef with cellular serine/threonine kinases is dispensable for the development of AIDS in rhesus macaques.
Nat. Med.
3:860-865[Medline].
|
| 27.
|
Miller, M. D.,
M. T. Warmerdam,
I. Gaston,
W. C. Greene, and M. B. Feinberg.
1994.
The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages.
J. Exp. Med.
179:101-114[Abstract/Free Full Text].
|
| 28.
|
Miller, M. D.,
M. T. Warmerdam,
K. A. Page,
M. B. Feinberg, and W. C. Greene.
1995.
Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry.
J. Virol.
69:579-584[Abstract].
|
| 29.
|
Morrison, H. G.,
F. Kirchhoff, and R. C. Desrosiers.
1995.
Effects of mutations in constant regions 3 and 4 of envelope of simian immunodeficiency virus.
Virology
210:448-455[Medline].
|
| 30.
|
Norley, S.,
B. Beer,
D. Binninger-Schinzel,
C. Cosma, and R. Kurth.
1996.
Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus.
Virology
219:195-205[Medline].
|
| 31.
|
Pandori, M. W.,
N. J. Fitch,
H. M. Craig,
D. D. Richman,
C. A. Spina, and J. C. Guatelli.
1996.
Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein.
J. Virol.
70:4283-4290[Abstract].
|
| 32.
|
Potts, B. J.
1990.
"Mini" reverse transcriptase assay, p. 103-106.
In
A. Aldovini, and B. D. Walker (ed.), Techniques in HIV research. Stockton, New York, N.Y.
|
| 33.
|
Regier, D. A., and R. C. Desrosiers.
1989.
The complete nucleotide sequence of a pathogenic molecular clone of SIV.
AIDS Res. Hum. Retroviruses
6:1221-1231.
|
| 34.
|
Rud, E. W.,
J. R. Jon,
B. A. Larder,
B. E. Clarke,
N. Cook, and M. P. Cranage.
1992.
Infectious molecular clone of SIVmac32H: nef deletion controls ability to reisolate virus from rhesus macaques.
Vaccines
92:229-235.
|
| 35.
|
Rud, E. W.,
M. Cranage,
J. Yon,
J. Quirk,
L. Ogilvie,
N. Cook,
S. Webster,
M. Dennis, and B. E. Clarke.
1994.
Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants.
J. Gen. Virol.
75:529-543[Abstract/Free Full Text].
|
| 36.
|
Salvi, R.,
A. R. Garbuglia,
A. Di Caro,
S. Pulciani,
F. Montella, and A. Benedetto.
1998.
Grossly defective nef gene sequences in a human immunodeficiency virus type 1-seropositive long-term nonprogressor.
J. Virol.
72:3646-3657[Abstract/Free Full Text].
|
| 37.
|
Schwartz, O.,
V. Marechal,
O. Danos, and J. M. Heard.
1995.
Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell.
J. Virol.
69:4053-4059[Abstract].
|
| 38.
|
Schwartz, O.,
V. Marechal,
S. Le Gall,
F. Lemonnier, and J. M. Heard.
1996.
Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein.
Nat. Med.
2:338-342[Medline].
|
| 39.
|
Sharpe, S. A.,
A. M. Whatmore,
G. A. Hall, and M. P. Cranage.
1997.
Macaques infected with attenuated simian immunodeficiency virus resist superinfection with virulence-revertant virus.
J. Gen. Virol.
78:1923-1927[Abstract].
|
| 40.
|
Shibata, R.,
C. Siemon,
S. C. Czajak,
R. C. Desrosiers, and M. A. Martin.
1997.
Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.
J. Virol.
71:8141-8148[Abstract].
|
| 41.
|
Skowronski, J., and R. Mariani.
1995.
Transient assay for Nef-induced down-regulation of CD4 antigen expression on the cell surface, p. 231-242.
In
D. Rickwood, B. D. Hames, and J. Karn (ed.), HIV-1: a practical approach. IRL Press/Oxford University Press, Oxford, England.
|
| 42.
|
Spina, C. A.,
T. J. Kwoh,
M. Y. Chowers,
J. C. Guatelli, and D. D. Richman.
1994.
The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes.
J. Exp. Med.
179:115-123[Abstract/Free Full Text].
|
| 43.
|
Stahl-Hennig, C.,
U. Dittmer,
T. Nisslein,
H. Petry,
E. Jurkiewicz,
D. Fuchs,
H. Wachter,
K. Matz-Rensing,
E. M. Kuhn,
F. J. Kaup,
E. W. Rud, and G. Hunsmann.
1996.
Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus.
J. Gen. Virol.
77:2969-2981[Abstract/Free Full Text].
|
| 44.
|
Titti, F.,
L. Sernicola,
A. Geraci,
G. Panzini,
S. Di-Fabio,
R. Belli,
F. Monardo,
A. Borsetti,
M. T. Maggiorella,
M. Koanga-Mogtomo,
F. Corrias,
R. Zamarchi,
A. Amadori,
L. Chieco-Bianchi, and P. Verani.
1997.
Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys.
J. Gen. Virol.
78:2529-2539[Abstract].
|
| 45.
|
Whatmore, A. M.,
N. Cook,
G. A. Hall,
S. Sharpe,
E. W. Rud, and M. P. Cranage.
1995.
Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence.
J. Virol.
69:5117-5123[Abstract].
|
| 46.
|
Wyand, M. S.,
K. H. Manson,
M. Garcia-Moll,
D. Monfiori, and R. C. Desrosiers.
1996.
Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.
J. Virol.
70:3724-3733[Abstract].
|
Journal of Virology, April 1999, p. 2790-2797, Vol. 73, No. 4
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Brenner, M., Munch, J., Schindler, M., Wildum, S., Stolte, N., Stahl-Hennig, C., Fuchs, D., Matz-Rensing, K., Franz, M., Heeney, J., Ten Haaft, P., Swigut, T., Hrecka, K., Skowronski, J., Kirchhoff, F.
(2006). Importance of the N-Distal AP-2 Binding Element in Nef for Simian Immunodeficiency Virus Replication and Pathogenicity in Rhesus Macaques. J. Virol.
80: 4469-4481
[Abstract]
[Full Text]
-
Schindler, M., Munch, J., Brenner, M., Stahl-Hennig, C., Skowronski, J., Kirchhoff, F.
(2004). Comprehensive Analysis of Nef Functions Selected in Simian Immunodeficiency Virus-Infected Macaques. J. Virol.
78: 10588-10597
[Abstract]
[Full Text]
-
Munch, J., Adam, N., Finze, N., Stolte, N., Stahl-Hennig, C., Fuchs, D., Ten Haaft, P., Heeney, J. L., Kirchhoff, F.
(2001). Simian Immunodeficiency Virus in Which nef and U3 Sequences Do Not Overlap Replicates Efficiently In Vitro and In Vivo in Rhesus Macaques. J. Virol.
75: 8137-8146
[Abstract]
[Full Text]